# BPC-157 TB-500 References: The Cited Record and FDA Sources

> BPC-157 TB-500 references: every cited study behind the two-peptide blend — the BPC-157 and Thymosin Beta-4 literature, recent reviews, and the audited FDA 503A compounding sources.

Every claim on this site resolves to one of these — the constituent literature, the recent reviews, and the audited FDA compounding sources.

## How to read this register

These are the BPC-157 TB-500 references behind every quantitative claim on the site. The list divides into three registers. References 1-8 are the foundational constituent literature — the BPC-157 tendon and pharmacokinetic work and the Thymosin Beta-4 mechanism and human-safety studies. References 9-11 are recent reviews (2025-2026) that bound the evidence honestly. References 12-14 are the audited FDA sources for the compounding and access status on the legal-status page. Each entry below carries its journal, year, DOI, and PubMed or FDA link so any claim can be traced to source.

## Constituent literature

The eight foundational studies span both legs of the blend: the BPC-157 transected-Achilles-tendon result [1], the BPC-157 VEGFR2 angiogenesis mechanism [2], the Thymosin Beta-4 actin-sequestration crystal structure [3], the consolidated Thymosin Beta-4 mechanism review [4], the first formal BPC-157 pharmacokinetic/ADME characterization [5], two human Phase 1 safety studies of full-length and recombinant Thymosin Beta-4 [6][7], and the chemical synthesis that defines the TB-500 heptapeptide itself [8]. The full citations are listed in the reference register.

## Recent reviews and the audited FDA sources

Three recent reviews frame the current evidence: a 2025 systematic review of BPC-157 in orthopaedic sports medicine [9], a 2026 narrative review of approved and unapproved peptides for musculoskeletal injury and athletic performance [10], and a 2025 narrative review weighing regeneration against risk for BPC-157 [11]. The regulatory entries — the FDA Category 2 safety-risks list [12], the FDA Section 503A compounding framework [13], and the FDA July 23-24, 2026 advisory-committee meeting calendar [14] — are the audited sources for the legal-status page. The full citations follow in the reference register.

## References

[1] Staresinic M, et al. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating muscle healing; effects on transected rat Achilles tendon and in vitro tendocyte growth. J Orthop Res. 2003;21(6):976-983. https://pubmed.ncbi.nlm.nih.gov/14554208/
[2] Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. https://pubmed.ncbi.nlm.nih.gov/27847966/
[3] Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004;23(18):3599-3608. https://pubmed.ncbi.nlm.nih.gov/15329672/
[4] Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. https://pubmed.ncbi.nlm.nih.gov/22074294/
[5] Wang Y, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. https://pubmed.ncbi.nlm.nih.gov/36588717/
[6] Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010;1194:223-229. https://pubmed.ncbi.nlm.nih.gov/20536472/
[7] A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta4 in healthy Chinese volunteers. J Cell Mol Med. 2021;25(16):7866-7875. https://pubmed.ncbi.nlm.nih.gov/34346165/
[8] Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. https://pubmed.ncbi.nlm.nih.gov/22962027/
[9] Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. https://pubmed.ncbi.nlm.nih.gov/40756949/
[10] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. https://pubmed.ncbi.nlm.nih.gov/41966639/
[11] Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. https://pubmed.ncbi.nlm.nih.gov/40789979/
[12] U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. Category 2 list entries for 'BPC-157' and 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500'; effective with the September 29, 2023 update to the list of bulk drug substances nominated for use under section 503A. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
[13] U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. Definitions of the Category 1 / Category 2 interim-policy framework and the 503A/503B compounding pathway. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
[14] U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Public calendar listing BPC-157 and TB-500 among bulk drug substances 'being considered for inclusion on the 503A Bulks List' (a scheduled discussion of substances under evaluation, not a decision). https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026

---

A dark-gallery digest of the BPC-157 and TB-500 record — every study hung as a cited specimen, the access status read first, and no clinic, vendor, or prescription behind the glass.